News You Need to Know Today
Coronary Intervention & Surgery | March 2018
Thursday, March 22, 2018
Long-term survival benefit seen in on-pump vs off-pump CABG

There is a small but significant long-term survival benefit of on-pump coronary artery bypass graft (CABG) surgery when compared to off-pump procedures, according to a meta-analysis published online Feb. 26 in the Journal of the American College of Cardiology.

TCT paradox: Patients more likely to survive MI during interventional cardiology conference

Patients hospitalized with acute myocardial infarction (AMI) actually fare better when some of the top minds in interventional cardiology are away at the annual Transcatheter Cardiovascular Therapeutics (TCT) meeting, suggests a study published March 9 in the Journal of the American Heart Association.

Abnormal glucose levels common in ‘nondiabetic’ PCI patients, tied to worse outcomes

Roughly one-third of patients without known diabetes in a PCI trial had abnormal glucose readings and demonstrated up to a four-fold risk of adverse outcomes within one year, researchers reported in JACC: Cardiovascular Interventions.

Medtronic’s 2 mm DES gains FDA approval, becomes smallest on market

The FDA has approved Medtronic's two-millimeter Resolute Onyx drug-eluting stent (DES), making it the smallest DES on the U.S. market.

Higher mortality rates in women after PCI driven by noncardiac causes

The higher rates of all-cause mortality after percutaneous coronary intervention (PCI) observed in women can be attributed to noncardiac factors, suggests a single-center study published in Circulation: Cardiovascular Interventions.

No significant differences in efficacy, safety between drug-eluting stents

There are few significant differences in target-vessel failure with second generation drug-eluting stents (DES) for patients with left main coronary artery disease (LMCAD), according to research published on Feb. 27 in the Journal of the American College of Cardiology.

  



Copyright © *|CURRENT_YEAR|* | TriMed Media | All Rights Reserved.

 Editorial Questions  Advertising Inquiries  Client Services  Update Profile

This message was sent to *|EMAIL|*. Please add *|LIST:EMAIL|* to your address book, contacts or "Safe Senders" list.
If you prefer not to receive messages like this in the future, click here to remove yourself from this list.

TriMed Media | 29 E Madison Street, Suite 440 | Chicago, IL 60602 USA